Table 1 Demographics and Behçet’s disease characteristics of the participants
The cohort for neutrophil mass spectrometry | The cohort for serum mass spectrometry | |||
|---|---|---|---|---|
Sample | BD | HC | BD | HC |
Number | N = 24 | N = 24 | N = 23 | N = 23 |
Age (median, (range)) | 35(26-57) | 35(25–56) | 34(20–58) | 35(22–56) |
Gender, Male (n, (%)) | 16(66.67) | 16(66.67) | 15(65.22) | 15(65.22) |
Clinical manifestation (n, (%)) | ||||
Oral ulcer | 24(100) | NA | 23(100) | NA |
Genital ulcer | 15(62.5) | NA | 12(52.17) | NA |
Skin lesions | 4(16.67) | NA | 3(13.04) | NA |
Gastrointestinal involvement | 9(37.5) | NA | 5(21.74) | NA |
Uveitis | 3(12.5) | NA | 1(4.35) | NA |
Neurological involvement | 0 | NA | 1(4.35) | NA |
Arthralgia / Arthritis | 5(20.83) | NA | 5(21.74) | NA |
Vascular involvement | 11(45.83) | NA | 15(65.22) | NA |
Thrombus | 4(16.67) | NA | 9(39.13) | NA |
Aneurysm | 2(8.33) | NA | 6(26.09) | NA |
Cardiac valve involvement | 6(25) | NA | 3(13.04) | NA |
Treatment (n, (%)) | ||||
Treatment-naive | 17(70.83) | NA | 19(82.61) | NA |
Undertreatment | 7(29.17) | NA | 4(17.39) | NA |
Glucocorticosteroid | 6(25) | NA | 3(13.04) | NA |
Immunosuppressant | 6(25) | NA | 4(17.39) | NA |
Biologics | 3(12.5) | NA | 2(8.70) | NA |
Disease evaluation | ||||
BDCAF (median, (range)) | 1(0–3) | NA | 2(0–4) | NA |
ESR (median, (range), mm/h) | 18.5(7–75) | NA | 40(11–140) | NA |
CRP (median, (range), mg/L) | 19.09(6–108.09) | NA | 51.53(13.6–85.35) | NA |
Severity score (median, (range)) | 3(2–7) | NA | 4(2–7) | NA |
Follow-up (mean ± SD, month) | 5(3–26) | NA | 27(12–60) | NA |
